{"id":1012939,"date":"2026-10-22T18:40:28","date_gmt":"2026-10-22T22:40:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/"},"modified":"2026-10-22T18:40:28","modified_gmt":"2026-10-22T22:40:28","slug":"charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/","title":{"rendered":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment"},"content":{"rendered":"

<\/p>\n

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment<\/b><\/p>\n

Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-making<\/i><\/p>\n

WILMINGTON, Mass.–(BUSINESS WIRE<\/a>)–
\nCharles River Laboratories International, Inc. (NYSE: CRL) today announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations (ADFs) and emerging drugs of abuse. The agreement establishes a joint research framework to enhance objective, standardized metrics for quantifying abuse potential in preclinical models<\/a> which may inform regulatory assessments of abuse potential under the Controlled Substances Act (CSA).<\/p>\n

\n\u201cAssessing abuse potential is essential for identifying risks and ensuring the safety of new drugs,\u201d said Dr. Namandj\u00e9 N. Bumpus, Chief Science and Innovation Officer, Charles River. \u201cThis collaboration will improve public health safeguards and ultimately amplify our shared efforts to protect patients and communities.\u201d<\/p>\n

Evaluating Abuse Potential
\n
<\/b>Abuse potential assessments are vital components of the safety evaluation of central nervous system-active compounds and are relied upon by FDA and the Drug Enforcement Administration for scheduling control measures.<\/p>\n

\nEnhancing objective, reproducible methods to assess abuse potential is important for advancing regulatory science and supporting evidence-based decision-making. This collaboration will help evaluate approaches that could improve the consistency and sensitivity of abuse potential assessments, ultimately contributing to efforts to protect public health.<\/p>\n

\nCharles River has extensive expertise in assessing abuse potential, having conducted over 100 abuse potential studies and contributed to assessments of the abuse potential of 15 FDA-approved products. As part of its participation in the collaboration, Charles River will leverage behavioral economic models of supply and demand to analyze self-administration data. These models assess the relative reinforcing properties of substances, helping researchers evaluate abuse potential and compare it with that of known drugs of abuse. A recent behavioral economics pilot conducted at Charles River\u2019s Mattawan site provided preliminary proof-of-concept data that demonstrated the promise of this approach.<\/p>\n

\nThe collaboration aims to improve sensitivity, accuracy, and consistency across laboratories, ultimately enhancing public health by more reliably and effectively assessing the abuse potential of new drugs.<\/p>\n

About Charles River
\n
<\/b>Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261022662205\/en\/<\/a><\/span><\/p>\n

Charles River Investor Contact:
\n
<\/b>Todd Spencer
\n
Corporate Vice President,
\n
Investor Relations
\n
781.222.6455
\n
todd.spencer@crl.com<\/a><\/p>\n

Charles River Media Contact:
\n
<\/b>Amy Cianciaruso
\n
Corporate Senior Vice President,
\n
Chief Communications Officer
\n
781.222.6168
\n
amy.cianciaruso@crl.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Manufacturing FDA Health General Health Pharmaceutical Medical Devices Research Other Manufacturing Science Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-making WILMINGTON, Mass.–(BUSINESS WIRE)– Charles River Laboratories International, Inc. (NYSE: CRL) today announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations (ADFs) and emerging drugs of abuse. The agreement establishes a joint research framework to enhance objective, standardized metrics for quantifying abuse potential in preclinical models which may inform regulatory assessments of abuse potential under the Controlled Substances Act (CSA). \u201cAssessing abuse potential … <\/p>\n

Continue reading “Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012939","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCharles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-making WILMINGTON, Mass.–(BUSINESS WIRE)– Charles River Laboratories International, Inc. (NYSE: CRL) today announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations (ADFs) and emerging drugs of abuse. The agreement establishes a joint research framework to enhance objective, standardized metrics for quantifying abuse potential in preclinical models which may inform regulatory assessments of abuse potential under the Controlled Substances Act (CSA). \u201cAssessing abuse potential … Continue reading "Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T22:40:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment\",\"datePublished\":\"2026-10-22T22:40:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/\"},\"wordCount\":530,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/\",\"name\":\"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-10-22T22:40:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/","og_locale":"en_US","og_type":"article","og_title":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Market Newsdesk","og_description":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-making WILMINGTON, Mass.–(BUSINESS WIRE)– Charles River Laboratories International, Inc. (NYSE: CRL) today announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs, including abuse-deterrent formulations (ADFs) and emerging drugs of abuse. The agreement establishes a joint research framework to enhance objective, standardized metrics for quantifying abuse potential in preclinical models which may inform regulatory assessments of abuse potential under the Controlled Substances Act (CSA). \u201cAssessing abuse potential … Continue reading \"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T22:40:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment","datePublished":"2026-10-22T22:40:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/"},"wordCount":530,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/","name":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-10-22T22:40:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261022662205r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-labcorp-and-fda-collaborate-to-validate-new-preclinical-methods-for-abuse-potential-assessment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012939"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012939\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}